Researcher Profile

Researcher Profile

Matthew G. Kaag, MD

Matthew G. Kaag, MD

Associate Professor, Department of Surgery
Division of Urology
Scientific Program:Cancer Control
Disease Teams:
Genitourinary Cancer

Research Interests

  • Neoplasms
  • Urinary Bladder Neoplasms
  • Carcinoma
  • Kidney
  • Renal Cell Carcinoma
  • Therapeutics
  • Nephrectomy
  • Drug Therapy
  • Recurrence
  • Survival
  • Cystectomy
  • Muscles

Clinical Trials

Enhancing Patient Resilience During Multimodal Therapy for Bladder Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome

Recent Publications


Buckwalter, JM, Chan, W, Shuman, L, Wildermuth, T, Ellis-Mohl, J, Walter, V, Warrick, J, Wu, XR, Kaag, MG, Raman, J & Degraff, D 2019, 'Characterization of histone deacetylase expression within in vitro and in vivo bladder cancer model systems', International journal of molecular sciences, vol. 20, no. 10, 2599.
Kaag, MG 2019, 'Editorial Comment', Journal of Urology, vol. 202, no. 1.
Zaleski, M, Gogoj, A, Walter, V, Raman, J, Kaag, MG, Merrill, S, Drabick, J, Joshi, M, Holder, S, Degraff, D & Warrick, J 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system' Human Pathology, vol. 84, pp. 275-282.
Bodo, S, Campagne, C, Thin, TH, Higginson, DS, Vargas, HA, Hua, G, Fuller, JD, Ackerstaff, E, Russell, J, Zhang, Z, Klingler, S, Cho, HJ, Kaag, MG, Mazaheri, Y, Rimner, A, Manova-Todorova, K, Epel, B, Zatcky, J, Cleary, CR, Rao, SS, Yamada, Y, Zelefsky, MJ, Halpern, HJ, Koutcher, JA, Cordon-Cardo, C, Greco, C, Haimovitz-Friedman, A, Sala, E, Powell, SN, Kolesnick, R & Fuks, Z 2019, 'Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury', Journal of Clinical Investigation, vol. 129, no. 2, pp. 786-801.


Merrill, S, Sohl, BS, Hamirani, A, Lehman, EB, Lehman, KK, Kaag, MG & Raman, J 2019, 'Capturing Renal Cell Carcinoma Recurrences When Asymptomatic Improves Patient Survival', Clinical Genitourinary Cancer, vol. 17, no. 2, pp. 132-138.
Blair, BM, Robyak, H, Clark, JY, Kaag, MG, Lehman, EB & Raman, J 2018, 'Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center', Prostate International, vol. 6, no. 3, pp. 110-114.
Warrick, J, Sjödahl, G, Kaag, MG, Raman, J, Merrill, S, Shuman, L, Chen, G, Walter, V & Degraff, D 2019, 'Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants [Figure presented]', European Urology, vol. 75, no. 1, pp. 18-22.
Blair, BM, Lehman, EB, Jafri, SM, Kaag, MG & Raman, J 2018, 'Predicted versus observed 30-day perioperative outcomes using the ACS NSQIP surgical risk calculator in patients undergoing partial nephrectomy for renal cell carcinoma' International Urology and Nephrology, vol. 50, no. 7, pp. 1249-1256.
Kaag, MG & Raman, J 2018, 'Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer', Translational Andrology and Urology, vol. 7, pp. S732-S734.
Park, R, Gyorfi, J, Dewan, K, Kirimanjeswara, GS, Clark, JY, Kaag, MG, Lehman, K & Raman, J 2018, 'Topical rectal antiseptic at time of prostate biopsy: how a resident patient safety project has evolved into institutional practice', International Urology and Nephrology, vol. 50, no. 9, pp. 1563-1568.


Shah, TS, Kaag, MG, Raman, J, Chan, W, Tran, T, Kunchala, S, Shuman, L, Degraff, D, Chen, G & Warrick, J 2017, 'Clinical significance of prominent retraction clefts in invasive urothelial carcinoma', Human Pathology, vol. 61, pp. 90-96.
Harshman, LC, Tripathi, A, Kaag, MG, Efstathiou, JA, Apolo, AB, Hoffman-Censits, JH, Stadler, WM, Yu, EY, Bochner, BH, Skinner, EC, Downs, T, Kiltie, AE, Bajorin, DF, Guru, K, Shipley, WU, Steinberg, GD, Hahn, NM & Sridhar, SS 2018, 'Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer', Clinical Genitourinary Cancer, vol. 16, no. 3, pp. 213-218.
Warrick, J, Kaag, MG, Raman, J, Chan, W, Tran, T, Kunchala, S, Shuman, L, Degraff, D & Chen, G 2017, 'FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma', Virchows Archiv, vol. 471, no. 3, pp. 337-345.


Kaag, MG & Raman, J 2016, 'Clinical guidelines: Clearing murky water-a guideline-based approach to haematuria' Nature Reviews Urology, vol. 13, no. 5, pp. 243-244.
Al-Marrawi, MY, Mackley, H, Ali, S, Wagner Jr., H, Joshi, M, Holder, S, Kaag, MG, Mallon, C, Talamo, G & Drabick, J 2016, 'Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review', Clinical Genitourinary Cancer, vol. 14, no. 4, pp. e393-e399.
Warrick, J, Raman, J, Kaag, MG, Bruggeman, T, Cates, J, Clark, P & Degraff, D 2016, 'Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer', Urologic Oncology: Seminars and Original Investigations, vol. 34, no. 6, pp. 258.e1-258.e6.
Warrick, J, Walter, V, Yamashita, H, Chung, E, Shuman, L, Amponsa, VO, Zheng, Z, Chan, W, Whitcomb, T, Yue, F, Iyyanki, T, Imamura, Y, Kaag, MG, Guo, W, Raman, J, Park, JS & Degraff, D 2016, 'FOXA1, GATA3 and PPARIγ Cooperate to drive luminal subtype in bladder cancer: A molecular analysis of established human cell lines', Scientific reports, vol. 6, 38531.
Yin, M, Joshi, M, Meijer, RP, Glantz, M, Holder, S, Harvey, H, Kaag, MG, Van De Putte, EEF, Horenblas, S & Drabick, J 2016, 'Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis', Oncologist, vol. 21, no. 6, pp. 708-715.
Joshi, M, Vasekar, M, Grivas, P, Emamekhoo, H, Hsu, JA, Miller, VA, Stephens, PJ, Ali, SM, Ross, JS, Zhu, J, Warrick, J, Drabick, J, Holder, S, Kaag, MG, Li, M & Pal, SK 2016, 'Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma', Oncotarget, vol. 7, no. 32, pp. 52442-52449.
Yin, M, Wang, W, Rosenberg, J, Kaag, MG, Joshi, M, Holder, S, Tuanquin, L & Drabick, J 2016, 'Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review', Clinical Genitourinary Cancer, vol. 14, no. 2, pp. e203-e206.


Eggener, SE, Clark, MA, Shikanov, S, Smith, B, Kaag, MG, Russo, P, Wheat, JC, Wolf, JS, Matin, SF, Huang, WC, Harel, M, Cambio, J, Shalhav, AL & Raman, J 2015, 'Impact of warm versus cold ischemia on renal function following partial nephrectomy', World Journal of Urology, vol. 33, no. 3, pp. 351-357.
Warrick, J, Kaag, MG, Raman, J, Chan, W, Tran, T, Kunchala, S, Degraff, D & Chen, G 2015, 'Squamous Dysplasia of the Urinary Bladder', International Journal of Surgical Pathology, vol. 24, no. 4, pp. 306-314.
Apolo, AB, Hoffman, V, Kaag, MG, Latini, DM, Lee, CT, Rosenberg, JE, Knowles, M, Theodorescu, D, Czerniak, BA, Efstathiou, JA, Albert, ML, Sridhar, SS, Margulis, V, Matin, SF, Galsky, MD, Hansel, D, Kamat, AM, Flaig, TW, Smith, AB, Messing, E, Zipursky Quale, D & Lotan, Y 2015, 'Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward', Urologic Oncology: Seminars and Original Investigations, vol. 33, no. 2, pp. 53-64.
Wang, W, Cheng, J, Mallon, C, Al-Marrawi, MY, Holder, S, Joshi, M, Kaag, MG, Talamo, G & Drabick, J 2015, 'Symptomatic secondary polycythemia induced by anti-VEGF therapy for the treatment of metastatic renal cell carcinoma: A case series and review' Clinical Genitourinary Cancer, vol. 13, no. 6, pp. e391-e395.
Lipkin, JS, Rizvi, SM, Gatalica, Z, Sarwani, N, Holder, S, Kaag, MG, Drabick, J & Joshi, M 2015, 'Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression', Cancer biology & therapy, vol. 16, no. 1, pp. 28-33.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)